Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Technology appraisal guidance
Reference number: TA275
Published: 27 February 2013
Last updated: 02 July 2021

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: evaluation report

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: pre-meeting briefing
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Evidence Review Group report - factual accuracy check
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: erratum to the Evidence Review Group report
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: manufacturer submission
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: clarification
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: patient group, professional and NHS organisation submission statements
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: expert written personal statements

This page was last updated: 20 March 2014